Ivermectin, SARS-CoV-2
Conditions
Brief summary
The study aims to test whether Ivermectin would decrease mortality and reduces chances of getting infected with corona virus, improve management of clinical symptoms and reduce length of stay in ICU and transition probabilities to ICU (ventilator).
Detailed description
With the onset of global pandemic of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and the sharp rise in infection and mortality rates, efficient management of the current medical emergency has become an absolute priority. A lot of resources have been directed to developing a comprehensive therapeutic approach to preventing and curing this disease, and this has mostly been in western countries. However, lack of definite treatment, high number of infected people, limited capacity and the impact of COVID-19 on existing health infrastructure has left biomedical researchers and clinicians faced with the mammoth task of providing appropriate clinical care solutions and strategies with favorable cost-benefit outcomes, which can help in both curbing the disease and treating patients. To meet this challenge, repurposing of available drugs has become vital. Evidence from several recent clinical trials on the effects of available therapeutic clinical drugs and vitamin supplements on mortality rate and other clinical outcomes associated with COVID-19 are promising, however, the efficacy, safety, and appropriate dosing of therapeutic clinical drugs such as ivermectin, remain largely unevaluated in Sub-Saharan Africa. The investigators propose to evaluate and compare the efficacy of ivermectin in the management of Covid-19.
Interventions
DRUGIvermectin
Treatment of SARS Cov-2 patients with Ivermectin
OTHERProphylaxis
Treatment of high risk population with Ivermectin as prophylaxis
Sponsors
Ministry of Health, Zambia
University of Zambia
Centre for Infectious Disease Research in Zambia
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
Patients with moderate to severe COVID-19 disease will be randomized to either Ivermectin (Intervention) or Standard of Care (Control arm) in a 1:1 ratio.
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Individuals diagnosed positive for SARS-CoV-2 by real-time reverse transcription PCR (rRT-PCR with presence of a fever, cough, and/or sore throat.
Exclusion criteria
* Patients will be excluded if they report to be allergic to ivermectin or if there is potential for a drug-drug interaction with ivermectin; * Have chronic illnesses (e.g., ischemic heart disease, heart failure, documented cardiomyopathy, chronic kidney disease, chronic liver disease); * Have received ivermectin in the last 7 days; are pregnant or lactating; * Or have participated in any other clinical trial within the last month.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| All-cause COVID-19 related mortality | within 28 days of enrollment | All-cause COVID-19 related mortality |
| COVID-19 Infection | Study duration | the proportion of patients on Ivermectin prophylaxis who test positive for COVID 19 using PCR after initially testing negative at enrolment |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Patient cure rate | 14- 28 days | The percentage of cured patients, defined as symptoms free to be discharged from the hospital and the percentage Changes of WHO's OSCI scale for COVID-19 between baseline and day 14 and between baseline and day 28. The study will will also evaluate the time to cure in both groups by measuring time from admission of the patient to the hospital till discharge. |
| Participant Infection Rate | 90 days | determine proportion who will develop severe disease and needing admission in addition to the above outcomes. |
Countries
Zambia
Outcome results
None listed